PUBLISHER: DelveInsight | PRODUCT CODE: 1576910
PUBLISHER: DelveInsight | PRODUCT CODE: 1576910
Ovarian Cancer Market Insight, Epidemiology And Market Forecast - 2034
Ovarian Cancer Market
Key Highlights:
Ovarian cancer, accounting for 3% of women's cancers, is a deadly form that originates in the ovaries, fallopian tubes, or peritoneum. It includes epithelial, germ cell, and stromal tumors, each derived from distinct ovarian cell types. Epithelial tumors, originating from surface cells, are the most common.
Early symptoms of ovarian cancer, like bloating and pelvic pain, can be subtle and easily overlooked. Advanced signs include changes in bowel habits and fatigue. Risk factors include genetics, family history, and age, while protective factors include oral contraceptives and pregnancy.
The market is anticipated to witness a substantial positive shift owing to better uptake of existing drugs, the expected market launch of one-time gene therapies, and raised awareness.
The United States accounts for the largest market size of Ovarian Cancer, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
Ovarian cancer often has warning signs, but the earliest symptoms are vague and easy to dismiss. It may cause several signs and symptoms. The symptoms are often very subtle and easily mistaken for other, more common problems. Early symptoms include bloating, pelvic pain, frequent urination, and feeling full quickly with eating whereas advanced symptoms include changes in bowel habits, back pain, ascites, fatigue, and others.
Diagnosis of ovarian cancer starts with a detailed medical history and physical examination. The physical examination consists of a pelvic and rectal examination. Additionally, it should assess for signs of endocrine dysfunction, paraneoplastic syndromes, and metastatic disease, including inguinal or left supraclavicular lymphadenopathy, pleural effusion, and umbilical mass.
The goal of treatment for ovarian cancer is to surgically remove as much cancer as possible through debulking and then to provide what is called an adjuvant, or additional therapy, such as chemotherapy, to kill any possible remaining cancer cells in the body. Currently, there are several types of medications used for treatment purposes, namely PARP Inhibitors, Immunomodulators, Anti-angiogenic agents, platinum-containing compounds, and others. At times, combination therapy and dietary supplementation are also prescribed.
Some of the approved therapies- RUBRACA (Rucaparib), ZEJULA (Niraparib) and LYNPARZA (Olaparib).
In May 2024, Allarity Therapeutics completed a Phase II trial for stenoparib (2X-121) due to significant clinical benefits observed in the initial trial phases. The company plans to initiate a subsequent trial with the quickest path to regulatory submission for stenoparib.
DelveInsight's "Ovarian Cancer - Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Ovarian Cancer, historical and forecasted epidemiology as well as the Ovarian Cancer market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Ovarian Cancer market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Ovarian Cancer market size from 2020 to 2034. The report also covers current Ovarian Cancer treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Geography Covered:
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Ovarian Cancer Understanding and Treatment Algorithm
Ovarian Cancer Overview, Country-Specific Treatment Guidelines and Diagnosis
Ovarian cancer is a type of cancer that begins in the ovaries or nearby areas like the fallopian tubes and peritoneum. The ovaries, located on either side of the uterus, produce eggs for reproduction and female hormones like estrogen and progesterone.
Diagnosis of ovarian cancer starts with a detailed medical history and physical examination. The physical examination consists of a pelvic and rectal examination. Additionally, it should assess for signs of endocrine dysfunction, paraneoplastic syndromes, and metastatic disease, including inguinal or left supraclavicular lymphadenopathy, pleural effusion, and umbilical mass. There is no one test to diagnose OC, instead, the physicians take into consideration the symptoms together with the results of patient history, physical examination, biopsies, blood tests, and imaging scans- ultrasound, CT, and MRI. Other than this labs tests like Full Blood Count (FBC), Tumor Marker Tests, and Genetic testing, etc. are also performed.
Further details related to country-based variations in diagnosis are provided in the report
Ovarian Cancer Treatment
The goal of treatment for ovarian cancer is to surgically remove as much cancer as possible through debulking and then to provide what is called an adjuvant, or additional therapy, such as chemotherapy, to kill any possible remaining cancer cells in the body. Currently, there are several types of medications used for treatment purposes, namely PARP Inhibitors, Immunomodulators, Anti-angiogenic agents, platinum-containing compounds, and others. At times, combination therapy and dietary supplementation are also prescribed.
Ovarian Cancer Epidemiology
- The Ovarian Cancer epidemiology chapter in the report provides historical as well as forecasted in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2024 to 2034. Ovarian Cancer epidemiology is segmented with detailed insights into total diagnosed incident cases, age-specific cases, type-specific cases, stage-specific cases, and linewise treated cases of Ovarian Cancer.
- In the 7MM, the highest number of diagnosed incident cases of OC was observed in the US.
- The US accounted for ~35% of the diagnosed incident cases of OC in the 7MM in 2023.
- Among EU4 and the UK, the highest number of diagnosed incident cases of OC was observed in Germany.
- The highest cases of Ovarian Cancers were observed from high-grade serous epithelial type in 2023.
Table of Contents
1. Key Insights
2. Report Introduction
3. Ovarian Cancer Market Overview at a Glance
- 3.1. Market Share (%) Distribution of Ovarian Cancer in 2020
- 3.2. Market Share (%) Distribution of Ovarian Cancer in 2034
4. Executive Summary of Ovarian Cancer
5. Key Events
6. Epidemiology and Market Methodology
7. Disease Background and Overview
- 7.1. Introduction
- 7.2. Risk Factors and Causes
- 7.3. Signs and symptoms
- 7.4. Pathophysiology
- 7.5. Diagnosis of Ovarian Cancer
- 7.6. Diagnostic Algorithm
- 7.7. Diagnostic Tests
- 7.8. Differential Diagnosis
- 7.9. Diagnostic Guidelines
8. Treatment and Management of Ovarian Cancer
- 8.1. Treatment Algorithm
- 8.2. Treatment Guidelines
9. Epidemiology and Patient Population
- 9.1. Key Findings
- 9.2. Assumptions and Rationale
- 9.3. Total Diagnosed Incident Cases of Ovarian Cancer in the 7MM
- 9.4. United States
- 9.4.1. Total Diagnosed Incident Cases of OC in the US
- 9.4.2. Age-specific Cases of OC in the US
- 9.4.3. Type-specific Cases of OC in the US
- 9.4.4. Stage-specific Cases of OC in the US
- 9.4.5. Linewise Treated Cases of OC in the US
- 9.5. EU4 and the UK
- 9.5.1. Total Diagnosed Incident Cases of OC in EU4 and the UK
- 9.5.2. Age-specific Cases of OC in EU4 and the UK
- 9.5.3. Type-specific Cases of OC in EU4 and the UK
- 9.5.4. Stage-specific Cases of OC in EU4 and the UK
- 9.5.5. Linewise Treated Cases of OC in EU4 and the UK
- 9.6. Japan
- 9.6.1. Total Diagnosed Incident Cases of OC in Japan
- 9.6.2. Age-specific Cases of OC in Japan
- 9.6.3. Type-specific Cases of OC in Japan
- 9.6.4. Stage-specific Cases of OC in Japan
- 9.6.5. Linewise Treated Cases of OC in Japan
10. Patient Journey
11. Marketed Therapies
- 11.1. RUBRACA (rucaparib): Pharmaand GmbH
- 11.1.1. Drug Description
- 11.1.2. Regulatory Milestones
- 11.1.3. Other Developmental Activities
- 11.1.4. Clinical Development
- 11.1.5. Safety and Efficacy
- 11.2. ZEJULA (niraparib): GlaxoSmithKline
- 11.2.1. Drug Description
- 11.2.2. Regulatory Milestones
- 11.2.3. Other Developmental Activities
- 11.2.4. Clinical Development
- 11.2.5. Safety and Efficacy
12. Emerging Therapies
- 12.1. 2X-121 (stenoparib; E7449): Allarity Therapeutics
- 12.1.1. Drug Description
- 12.1.2. Other Developmental Activities
- 12.1.3. Clinical Development
- 12.1.4. Safety and Efficacy
- 12.2. VS-6766 (avutometinib): Allarity Therapeutics
- 12.2.1. Drug Description
- 12.2.2. Other Developmental Activities
- 12.2.3. Clinical Development
- 12.2.4. Safety and Efficacy
13. Ovarian Cancer Disease: 7 Major Market Analysis
- 13.1. Key Findings
- 13.2. Market Outlook
- 13.3. Conjoint Analysis
- 13.4. Key Market Forecast Assumptions
- 13.5. Total Market Size of Ovarian Cancer in the 7MM
- 13.6. Market Size of Ovarian Cancer by Therapies in the 7MM
- 13.7. United States
- 13.7.1. Total Market Size of Ovarian Cancer in the US
- 13.7.2. Market Size of Ovarian Cancer by Therapies in First Line in the US
- 13.7.3. Market Size of Ovarian Cancer by Therapies in Second Line in the US
- 13.7.4. Market Size of Ovarian Cancer by Therapies in Third Line in the US
- 13.7.5. Market Size of Ovarian Cancer by Therapies in Fourth Line and above in the US
- 13.8. EU4 and the UK
- 13.8.1. Total Market Size of Ovarian Cancer in EU4 and the UK
- 13.8.2. Market Size of Ovarian Cancer by Therapies in First Line in EU4 and the UK
- 13.8.3. Market Size of Ovarian Cancer by Therapies in Second Line in EU4 and the UK
- 13.8.4. Market Size of Ovarian Cancer by Therapies in Third Line in EU4 and the UK
- 13.8.5. Market Size of Ovarian Cancer by Therapies in Fourth Line and above in EU4 and the UK
- 13.9. Japan
- 13.9.1. Total Market Size of Ovarian Cancer in Japan
- 13.9.2. Market Size of Ovarian Cancer by Therapies in First Line in Japan
- 13.9.3. Market Size of Ovarian Cancer by Therapies in Second Line in Japan
- 13.9.4. Market Size of Ovarian Cancer by Therapies in Third Line in Japan
- 13.9.5. Market Size of Ovarian Cancer by Therapies in Fourth Line and above in Japan
14. KOL Views
15. SWOT Analysis
16. Unmet Needs
17. Market Access and Reimbursement
- 17.1. United States
- 17.1.1. Centre for Medicare and Medicaid Services (CMS)
- 17.2. EU4 and the UK
- 17.2.1. Germany
- 17.2.2. France
- 17.2.3. Italy
- 17.2.4. Spain
- 17.2.5. United Kingdom
- 17.3. Japan
- 17.3.1. MHLW
- 17.4. Reimbursement Scenario of Ovarian Cancer
18. Appendix
- 18.1. Bibliography
- 18.2. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
List of Tables
- Table 1: Total Incident Cases of Ovarian Cancer in the 7MM
- Table 2: Type-specific Incident cases of Ovarian Cancer in the 7MM(2020-2034)
- Table 3: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the 7MM (2019-2032)
- Table 4: Age-specific Incident Cases of Ovarian Cancer in the 7MM [2020-2034]
- Table 5: Total Treated Cases of Ovarian Cancer in the 7MM [2020-2034]
- Table 6: Total Incident Cases of Ovarian Cancer in the United States (2019-2032)
- Table 7: Type-specific Incident cases of Ovarian Cancer in the United States (2020-2034)
- Table 8: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the United States (2019-2032)
- Table 9: Age-specific Incident Cases of Ovarian Cancer in the United States [2020-2034]
- Table 10: Total Treated Cases of Ovarian Cancer in the United States [2020-2034]
- Table 11: Total Incident Cases of Ovarian Cancer in the EU-5 (2019-2032)
- Table 12: Type-specific Incident cases of Ovarian Cancer in the EU-5 (2020-2034)
- Table 13: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the EU-5 (2019-2032)
- Table 14: Age-specific Incident Cases of Ovarian Cancer in the EU-5 [2020-2034]
- Table 15: Total Treated Cases of Ovarian Cancer in the EU-5 [2020-2034]
- Table 16: Total Incident Cases of Ovarian Cancer in Japan (2020-2034)
- Table 17: Type-specific Incident cases of Ovarian Cancer in Japan (2020-2034)
- Table 18: Grade-specific Incident cases of Ovarian Cancer in Japan (2020-2034)
- Table 19: Age-specific Incident Cases of Ovarian Cancer in Japan [2020-2034]
- Table 20: Total Treated Cases of Ovarian Cancer in Japan (2020-2034)
- Table 21: AVB-500, Clinical Trials by Recruitment status, 2021
- Table 22: AVB-500, Clinical Trials by Zone, 2021
- Table 23: Total Seven Major Market Size in USD, Million (2020-2034)
- Table 24: 7MM-Market Size by Therapies in USD, Million (2020-2034)
- Table 25: United States Market Size in USD, Million (2020-2034)
- Table 26: United States Market Size by Therapies in USD, Million (2020-2034)
- Table 27: EU-5 Market Size in USD, Million (2019-2032)
- Table 28: EU-5 Market Size by Therapies in USD, Million (2020-2034)
- Table 29: Japan Market Size in USD, Million (2020-2034)
- Table 30: Japan Market Size by Therapies in USD, Million (2020-2034)
List of Figures
- Figure 1: Total Incident Cases of Ovarian Cancer in the 7MM
- Figure 2: Type-specific Incident cases of Ovarian Cancer in the 7MM(2020-2034)
- Figure 3: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the 7MM (2019-2032)
- Figure 4: Age-specific Incident Cases of Ovarian Cancer in the 7MM [2020-2034]
- Figure 5: Total Treated Cases of Ovarian Cancer in the 7MM [2020-2034]
- Figure 6: Total Incident Cases of Ovarian Cancer in the United States (2019-2032)
- Figure 7: Type-specific Incident cases of Ovarian Cancer in the United States (2020-2034)
- Figure 8: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the United States (2019-2032)
- Figure 9: Age-specific Incident Cases of Ovarian Cancer in the United States [2020-2034]
- Figure 10: Total Treated Cases of Ovarian Cancer in the United States [2020-2034]
- Figure 11: Total Incident Cases of Ovarian Cancer in the EU-5 (2019-2032)
- Figure 12: Type-specific Incident cases of Ovarian Cancer in the EU-5 (2020-2034)
- Figure 13: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the EU-5 (2019-2032)
- Figure 14: Age-specific Incident Cases of Ovarian Cancer in the EU-5 [2020-2034]
- Figure 15: Total Treated Cases of Ovarian Cancer in the EU-5 [2020-2034]
- Figure 16: Total Incident Cases of Ovarian Cancer in Japan (2020-2034)
- Figure 17: Type-specific Incident cases of Ovarian Cancer in Japan (2020-2034)
- Figure 18: Grade-specific Incident cases of Ovarian Cancer in Japan (2020-2034)
- Figure 19: Age-specific Incident Cases of Ovarian Cancer in Japan [2020-2034]
- Figure 20: Total Treated Cases of Ovarian Cancer in Japan (2020-2034)
- Figure 21: Total Seven Major Market Size in USD, Million (2020-2034)
- Figure 22: 7MM-Market Size by Therapies in USD, Million (2020-2034)
- Figure 23: United States Market Size in USD, Million (2020-2034)
- Figure 24: United States Market Size by Therapies in USD, Million (2020-2034)
- Figure 25: EU-5 Market Size in USD, Million (2019-2032)
- Figure 26: EU-5 Market Size by Therapies in USD, Million (2020-2034)
- Figure 27: Japan Market Size in USD, Million (2020-2034)
- Figure 28: Japan Market Size by Therapies in USD, Million (2020-2034)
